anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tic disorders are a class of childhood-onset neuropsychiatric disorders that occur in 1-3% of the population and often cause significant impairment in physical, social, academic, and interpersonal functioning and reduced quality of life. There is currently no cure for tic disorders, however large-scale randomized controlled trials have shown that a non-drug treatment known as Comprehensive Behavioral Intervention for Tics (CBIT) is more effective than supportive psychotherapy for reducing tics in both children and adults. Although CBIT is now recommended as a first-line intervention for tic disorders, many patients do not have access to CBIT, in part due to a lack of trained therapists. Given the need and desire for CBIT among individuals with tic disorders, high demand for therapist trainings, and the lack of therapists adequately trained in CBIT, there is a clear need for innovative ways to train more providers in this evidence-based treatment. To address this gap, the investigators recently developed an innovative online program for training therapists to deliver CBIT (called CBIT-Trainer). This study will test CBIT-Trainer against an intensive in-person therapist training program in a randomized controlled trial. This study will accomplish four aims: (1) to compare CBIT-Trainer to traditional in-person training on therapists' ability to administer CBIT with fidelity, (2) to compare CBIT-Trainer to in-person training on patient outcomes when patients are treated by a CBIT-trained therapist, (3) to identify therapist factors that might improve (or limit) adoption and use of CBIT-Trainer, and (4) to identify therapist factors likely to influence continued use of CBIT after training. These aims will be tested using an effectiveness-implementation hybrid randomized controlled trial comparing CBIT-Trainer (online therapist training) to the Tourette Association of America's Behavior Therapy Training Institute (in-person therapist training), which is the current gold-standard for training CBIT therapists. Therapist-patient dyads will be recruited to participate. The primary therapist outcome will be therapists' skill in delivering CBIT in a standardized role-play, which will be assessed at post-training (Week 0), after administering CBIT with a patient (Week 10), and at 6-month follow-up (Week 24). The primary patient outcome will be overall clinical improvement, which will be assessed at pre-treatment (Week 0), post-treatment (Week 10), and 6-month follow up (Week 24). Secondary therapist outcomes that will be assessed include changes in knowledge of tic disorders and CBIT; changes in comfort and self-efficacy in delivering CBIT; adherence to the CBIT protocol when treating a patient with tics; attitudes toward evidence-based practice and CBIT; and therapists' ratings of the acceptability, appropriateness, and feasibility of the training. Secondary patient outcomes that will be assessed include changes in motor and/or vocal tic severity; changes in overall psychological/behavioral, physical, and social functioning; and satisfaction with the treatment received.
Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.
Ameloblastic carcinomas are malignant tumors arising from the odontogenic epithelium and defined as having features of ameloblastic differentiation in addition to cytological features of malignancy. Orbital involvement is rare and generally involves invasion of the orbital floor, apex, or soft tissue. This report describes an advanced presentation of ameloblastic carcinoma with orbital invasion and provides a review of the literature. A 58-year-old male presented with a 2-year history of a mid-facial mass, causing intracranial invasion and distortion of most skull foramina, nasopharynx, nasal cavity, and both orbits. Notably, there was an en-plaque pattern of circumferential tracking of the tumor along both orbital walls without invasion beyond the extraconal space, causing compression of the orbital apex and proptosis. Histology demonstrated nests of ameloblastic carcinoma and the advanced tumor was deemed nonresectable, with treatment being palliative.
Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression.

The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
Paroxetine tablets, USP are indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment.

The efficacy of paroxetine was established in three 12-week trials in adult patients with social anxiety disorder (DSM-IV). Paroxetine has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY, Clinical Trials).

The effectiveness of paroxetine in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
We report co-occurrence of emphysematous cystitis and emphysematous pyelonephritis (EC/EPN) in a 64-year-old female with poor-controlled diabetes mellitus (DM) that presented with flank pain, fever, and hematuria that turned out to have a bilateral extrarenal pelvis. On examination, she was feverish, and the costovertebral angle was tender. By considering herhemoglobin A1C, her DM was out of control. Inflammatory markers elevated. Renal function tests were impaired. Urine culture was positive for extended-spectrum beta-lactamase Escherichia coli. Computed tomography scans (CT) confirmed the presence of air in the bladder and renal pelvis in favor of EC and unilateral EPN. We planned to use conservative treatments. Promptly intravenous antibiotics started; thereafter, the renal pelvis was drained via percutaneous catheter, and the bladder was drained via foley catheter, as well. After 14 days of hospitalization, clinical status improved, urine culture got negative, and emphysema in follow-up CT images wholly regressed. To our knowledge, co-occurrence of emphysematous cystitis (EC) and emphysematous pyelonephritis (EPN) in a patient with an extra renal pelvis never happened. We tend to convey messages, including (1) the extrarenal pelvis may contribute to predisposing the patient to pyelonephritis if it is considerably large; (2) the conservative plan and observation was a successful experience in treating extrarenal pelvis patients with EC/EPN.
In this study, all subjects were treated with TQB2450 (PD-L1 inhibitor) plus anlotinib combined with oxaliplatin and capecitabine, once every 3 weeks, six cycles of chemotherapy with oxaliplatin and capecitabine. Subsequently, TQB2450 (PD-L1 inhibitor) combined with anlotinib was maintained until disease progression, intolerable toxicity, withdrawal of informed consent, loss of follow-up or death, or other circumstances that the researcher judged should stop treatment, whichever occurred first.
The objective of the present invention is to provide a portable cosmetic water dispenser, wherein moisture is sprayed through an ultrasonic vibrator driven by a push button switch operation and a spray unit composed of a spray port so as to achieve skin management and maintenance such as moisturization of the skin and smoothing of the skin surface. The cosmetic water dispenser has a body which is divided into an upper portion and a lower portion, an ejection unit is provided on an outer surface of the body, and a bottom is provided as a lower surface of the body. Accordingly, the cosmetic water dispenser is composed of a water container filled with cosmetic water by an arrangement method and a torso of which a push button switch is provided on an outer surface, and in which electrical components are embedded. The water container and the torso are coupled to each other in a fit-to-fit manner by a male and female coupling structure by means of a band-shaped mediator. The cosmetic water dispenser includes: a rod-shaped suction member of which a horizontal part and a vertical part of an absorbent medium are embedded in a curved receiving tube installed on bottom in the water bottle, and which sucks up cosmetic water by a capillary action and supplies the cosmetic water to the spray unit; and an electrode unit in which a pair of positive and negative silver poles arranged in parallel to each other are immersed in cosmetic water and generate colloidal silver by electrolysis. A rear end of an upper portion of the receiving tube of the suction member is open, and the open rear end is opened and closed by a cap, and a coil spring is interposed between the cap and a rear surface of the horizontal part, such that a front surface of the horizontal part is in contact with the ultrasonic vibrator. Accordingly, the cosmetic water dispenser sucks up cosmetic water using the suction member, which is the absorbent medium of the water container, and the cosmetic water is indirectly supplied to the spray unit and sprayed through the spray unit.
The invention relates to a pharmaceutical composition to reduce back pain comprising two compounds: an opioid antagonist and a direct-acting alpha 2 adrenegic agonist. The Opioid antagonist is selected from the group consisting of alvimopan, nalmefene, naloxone, naltrexone, methylnaltrexone, nalorphine, and pharmaceutically acceptable salt. The direct-acting alpha 2 adrenegic agonist is selected from a group consisting of Apraclonidine, Brimonidine, Clonidine, Detomidine, Dexmedetomidine, Guanabenz, Guanfacine, Lofexidine, Medetomidine, Romifidine, Tizanidine, Tolonidine, Xylazine and Fadolmidine. In one embodiment, the composition may include naltrexone (or its pharmaceutically acceptable salt) as the opioid antagonist and clonidine hydrochloride (or its pharmaceutically acceptable salt) as the direct-acting alpha 2 adrenegic agonist. It is preferred naltrexone be administered with a second agent such as an antitussive, expectorant, decongestant, or antihistamine. The dosage of naltrexone may range between 0.25 mg to 15 mg, while the dosage of clonidine hydrochloride ranges between 0.0125 mg and 0.3 mg.
Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks.
The invention discloses a medical imaging material, and a preparation method and an application thereof. The material is obtained by carrying out sulfydryl PEG (polyethylene glycol) hydrophilic modification to a NaYbF4-based material doped with Tm<3+> ion, and shown as: NaYbF4:Tm<3+>@PEG. The preparation method for the medical imaging material comprises the following steps of: firstly, preparing NaYbF4:Tm<3+> hydrophobic nanometer particles by adopting a high-temperature pyrolysis method; and carrying out the sulfydryl PEG hydrophilic modification to the NaYbF4:Tm<3+> hydrophobic nanometer particles to obtain the medical imaging material. The medical imaging material disclosed by the invention can be applied to CT (Computed Tomography) imaging and/or near-infrared fluorescence imaging, has a good imaging effect, high sensitivity and cell hypotoxicity. Moreover, through the co-doping of the Gd<3+> ion, cooperative imaging of near-infrared fluorescence, CT and nuclear magnetism MR (Magnetic Resonance) is realized. The preparation method for the medical imaging material belongs to a multimode imaging technology, and has an important value and meaning to the development and application of the medical diagnosis technique.
The invention relates to application of a traditional Chinese medicine composition in preparation of traditional Chinese medicine composition for increasing collateral circulation after treatment of coronary heart disease stenting. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 8-12 parts of radix curcumae, 13-17 parts of codonopsis pilosula, 8-12 parts of radix polygonati officinalis, 3-7 parts of peach kernel and 5-15 parts of earthworm. The traditional Chinese medicine composition is prepared from the pure traditional Chinese medicines, is wide in case suiting range and does not have toxic or side effects. The medicine comprises few raw material components; the raw materials are abundant, readily available and low in price. The medicine is simple in preparation process and suitable for popularization and application. The traditional Chinese medicine has the effects of dilating coronary artery, resisting platelet aggregation and thrombogenesis, reducing the blood viscosity, improving the microcirculation, promoting angiogenesis and promoting endothelial repair and is short in course of treatment of myocardial ischemia and obvious in effect.
National efforts are underway to support the implementation of technology that enables providers to electronically access and view community-wide clinical information for their patients, which has the potential to improve quality of care and reduce health care costs by providing timely and complete health information at the point of care. However, few empirical studies have been conducted to evaluate the economic effects of this technology. Along with other stakeholders, New York State is funding regional health information organizations (RHIOs) to deploy a virtual health record (VHR), which is technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal. RHIOs bring together multiple stakeholders, including physician practices, hospitals, pharmacies, and laboratories, for the purpose of exchanging clinical information electronically across communities. The investigators will conduct a multi-RHIO retrospective pre-post, cohort study of adult patients who have consented to have their clinical data viewed by their providers using the VHR portal. Examining the effects of electronically accessing clinical data on healthcare utilization across multiple settings and communities can help inform the national health IT initiative that is underway and allow assessment of the economic value of these technologies.
PURPOSE: We previously described a combined risk score (CRS) that integrates a multiple-ancestry polygenic risk score (MA-PRS) with the Tyrer-Cuzick (TC) model to assess breast cancer (BC) risk. Here, we present a longitudinal validation of CRS in a real-world cohort.
METHODS: This study included 130,058 patients referred for hereditary cancer genetic testing and negative for germline pathogenic variants in BC-associated genes. Data were obtained by linking genetic test results to medical claims (median follow-up 12.1 months). CRS calibration was evaluated by the ratio of observed to expected BCs.
RESULTS: Three hundred forty BCs were observed over 148,349 patient-years. CRS was well-calibrated and demonstrated superior calibration compared with TC in high-risk deciles. MA-PRS alone had greater discriminatory accuracy than TC, and CRS had approximately 2-fold greater discriminatory accuracy than MA-PRS or TC. Among those classified as high risk by TC, 32.6% were low risk by CRS, and of those classified as low risk by TC, 4.3% were high risk by CRS. In cases where CRS and TC classifications disagreed, CRS was more accurate in predicting incident BC.
CONCLUSION: CRS was well-calibrated and significantly improved BC risk stratification. Short-term follow-up suggests that clinical implementation of CRS should improve outcomes for patients of all ancestries through personalized risk-based screening and prevention.
Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
Background Drug-related problems among the elderly population are common and increasing. Multi-professional medication reviews (MR) have arisen as a method to optimize drug therapy for frail elderly patients. Research has not yet been able to show conclusive evidence of the effect of MRs on mortality or hospital admissions. Aim The aim of this study was to assess the impact of MRs' on hospital admissions and mortality after six and 12 months in a frail population of 369 patients in primary care in a randomized controlled study. Methods Patients were blindly randomized to an intervention group (receiving MRs) and a control group (receiving usual care). Descriptive data on mortality and hospital admissions at six and 12 months were collected. Survival analysis was performed for time to death and time to the first hospital admission within 12 months.
The invention discloses a pharmaceutical composition yinshiwanhe scald plaster for treating scalds and its preparation method. The preparation method comprises preparing a paste in proportion: stir-frying dried and winnowed wheat particles with high heat into black charcoal, which is spread on the ground for 2-3 hours to release fire toxin, then mixing it with dried raw rhubarb pieces uniformly, conducting sieving through a sieve of 120 meshes, adding 50g of the drug powder into 50ml of sesame oil, carrying out bottling and leaving the plaster for standby use. The pharmaceutical composition of the invention has the efficacy of fast detumescence and pain relieving, rapid escharosis and healing, and toxicological and pharmacological tests prove that the pharmaceutical composition can reach all standards. With wide drug sources, the plaster of the invention cannot cause infection and suppuration and breeds no Pseudomonas aeruginosa when used for treating burns and scalds. Patients can easily accept the plaster when it is applied in them. With low requirements for treatment conditions, the plaster can be used for on-site treatment at home, in the field, construction camps, and battlefields. The plaster leaves no scar to patients when they are cured, causes no skin allergy, and has no toxic or side effect. If treatment with the plaster is immediate, no scar can be left, and no branch-like massive venous rete is left either. The plaster provided in the invention has the advantages of uncomplicated processing flow, simple and convenient preparation under high temperature.
Streptococcus equi subsp. zooepidemicus (SEZ) is a zoonotic bacterial pathogen that causes life-threatening infections and various diseases such as meningitis, endocarditis and pneumonia. With the use of antibiotics being severely restricted in the international community, an alternative to antibiotics is urgently needed against bacterial. In the present study, the herbal extract magnolol protected mice against SEZ infection, reflected by increased survival rate and reduced bacterial burden. A pro-inflammatory form of cell death occurred in SEZ-infected macrophage. Magnolol downregulated the expression of pyroptosis-related proteins and reduced the formation of cell membrane pores in infected macrophages to suppress the development of subsequent inflammation. We further demonstrated that magnolol directly suppressed SEZ-induced macrophage pyroptosis, which partially protected macrophages from SEZ infection. Our study revealed that magnolol suppressed inflammation and protected mice against SEZ infection, providing a possible treatment for SEZ infection.